Elena Ambrogini Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Associate Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

26 h-index 124 pubs 3,990 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Elena Ambrogini's research focuses on bone biology, with recent work investigating the mechanisms underlying age-associated bone loss and the role of senescent osteocytes in bone destruction. Her studies have explored the impact of specific molecular pathways, such as Piezo1 and osteoprotegerin expression, on bone density and resorption. Ambrogini has also examined the role of oxidized phospholipids in attenuating age-related bone loss in mouse models.

Her work extends to the microenvironment of cancer metastasis and its effect on bone. Recent publications have identified senescent osteocytes as contributors to bone destruction in breast cancer metastasis and have elucidated signaling axes, including NOTCH3-CXCL12 and CCL3-HMGB1, that regulate osteocyte function in multiple myeloma.

Ambrogini leads a research group at the University of Arkansas for Medical Sciences. Her research network includes extensive collaboration with colleagues at the same institution, such as Charles A. O’Brien, Hayley M. Sabol, Japneet Kaur, and Aric Anloague, with whom she shares numerous publications. Her scholarly output is marked by an h-index of 26 and over 3,900 citations across more than 120 publications, designating her as a highly cited researcher.

Metrics

h-index: 26
Publications: 124
Citations: 3,990

Selected Publications

Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)

1 citation DOI OpenAlex
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025)

2 citations DOI OpenAlex
Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans (2025)

DOI OpenAlex
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024)

8 citations DOI OpenAlex
Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer (2024)

DOI OpenAlex
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024)

3 citations DOI OpenAlex
Editorial: Pathophysiology of bone and mineral metabolism (2024)

DOI OpenAlex
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024)

10 citations DOI OpenAlex
OR27-02 The Bone Anabolic Effect Of An Antibody Blocking Oxidized Phospholipids Is Associated With An Increase In Wnt10b In Osteoblasts. (2023)

DOI OpenAlex
THU664 Discontinuation Of Low-dose Levothyroxine Therapy For Patients With Subclinical Hypothyroidism Is Feasible: A Pilot, Randomized, Double-blind, Placebo-controlled Trial (2023)

DOI OpenAlex